Vasomotor symptoms, the hot flashes and night sweats that disrupt the lives of millions of women during menopause, are among the most frequent and debilitating symptoms of the transition. They can impair work performance, reduce quality of life, disturb sleep, and drive up healthcare costs. For decades, the mainstay of treatment was menopause hormone therapy, which works well for many women under 60 and within ten years of their final period, but is contraindicated in women with a history of hormone-sensitive cancers, prior blood clots, stroke, or liver disease. Until recently, the only FDA-approved non-hormonal option was the antidepressant paroxetine, while most other non-hormonal drugs were used off-label with modest efficacy and tolerability problems that lead up to half of users to stop within three months.

Neurokinin-targeted therapies changed that landscape. These drugs work by modulating neurokinin receptor activity in the hypothalamus, the brain region that regulates body temperature and becomes dysregulated as estrogen declines. Elinzanetant blocks both NK-1 and NK-3 receptors, and has demonstrated rapid and sustained reductions in the frequency and severity of moderate-to-severe hot flashes in the pivotal Phase III OASIS trials, along with meaningful improvements in sleep disturbance and menopause-related quality of life. But the class has faced scrutiny. Fezolinetant, a selective NK-3 antagonist, has been linked to rare but serious liver injury, prompting an FDA boxed warning for hepatotoxicity and mandatory liver function monitoring in multiple countries. An earlier NK-3 antagonist, pavinetant, had its clinical development halted in 2017 after transient transaminase rises in a Phase II trial.

To build a more comprehensive picture of elinzanetant’s safety, researchers pooled data from four randomized, placebo-controlled trials: the Phase IIb SWITCH-1 study conducted from 2018 to 2019 and the Phase III OASIS-1, -2, and -3 trials conducted from 2021 to 2024. All four enrolled postmenopausal women aged 40 to 65 experiencing moderate-to-severe vasomotor symptoms from natural or surgical menopause. The OASIS-4 trial, which studied women with hormone receptor-positive breast cancer receiving endocrine therapy, was excluded because of its substantially different population. The analysis examined two windows: a placebo-controlled period covering the first 12 weeks, in which 765 women took elinzanetant 120 mg and 754 took placebo, and a full 52-week period including 1,113 women exposed to elinzanetant.

The results showed that half of the elinzanetant group, 50.8 percent, reported at least one treatment-emergent adverse event during the first 12 weeks, compared with 43.2 percent on placebo. Most events were mild or moderate. Headache, fatigue, and somnolence were the most common events, occurring in 7.5, 5.4, and 3.4 percent of elinzanetant users respectively, versus 4.2, 1.3, and 0.5 percent on placebo. Notably, these symptoms clustered in the early weeks: their frequency was the same or lower at 52 weeks than at 12 weeks, suggesting most affected women experienced them only at the start of treatment. Serious adverse events were rare in both groups, at 1.2 percent with elinzanetant and 0.9 percent with placebo over 12 weeks, and nearly all were judged unrelated to the drug. A single serious event, a generalized tonic-clonic seizure in a participant with a long history of epilepsy, was assessed as possibly related; rare seizure cases have since appeared in post-marketing surveillance, and caution is advised for women with seizure disorders.

Discontinuation rates told a similar story of early but limited intolerance. Over 12 weeks, 7.8 percent of elinzanetant users stopped treatment because of adverse events, versus 3.6 percent on placebo, with fatigue and headache the leading causes. Crucially, the discontinuation rate did not rise between 12 and 52 weeks, indicating that women who tolerated the drug initially were unlikely to abandon it later. The authors also noted that because the trials were double-blind, background symptoms of menopause itself, or side effects of permitted concomitant medications, could have been coincidentally attributed to placebo, complicating direct comparisons.

Liver safety was the analysis’s most anticipated finding. Elevated alanine or aspartate transaminases above three times the upper limit of normal appeared in just 0.5 percent of elinzanetant users over 12 weeks and 1.2 percent over 52 weeks, rates that were statistically indistinguishable from placebo. There were no elevations of five or eight times the upper limit during the placebo-controlled period, and no cases meeting the strict Hy’s law criteria that flag potential serious drug-induced liver injury. An independent blinded liver safety monitoring board reviewed all cases meeting close-observation thresholds and judged only one elinzanetant case possibly related, in a woman with a plausible alternative cause involving possible gallstone passage; that case resolved without stopping treatment. The authors point out that elinzanetant lacks the structural features associated with hepatotoxicity and shares no similar substructures with NK-3 antagonists, and that approved NK-1 antagonists have not been linked to liver injury. Most countries do not require liver monitoring with elinzanetant, though the FDA mandates baseline testing and a repeat check at three months.

Cancer risk, a second area of concern raised during fezolinetant’s development, also showed no troubling signal. Malignant tumors were reported in five elinzanetant-treated women, including one case of invasive triple-negative breast cancer judged unrelated to treatment, and two placebo-treated women with basal cell skin cancers. The exposure-adjusted incidence rate for malignant tumors in the elinzanetant group, 0.88 per 100 person-years, was broadly consistent with the population-level rate of 0.81 observed in US women aged 50 to 64 in the SEER cancer registry, and the breast cancer rate of 0.38 aligned with a background rate of 0.29. No cases of endometrial hyperplasia or malignancy emerged in either group, an important finding given that unopposed estrogen in hormone therapy can raise endometrial cancer risk. The researchers also observed that NK-1 receptor antagonists have demonstrated anti-tumor activity in preclinical cancer models, and that elinzanetant modulates neurokinin signaling without any estrogenic effect, offering no mechanistic route to hormone-related cancers. Metabolic markers including blood pressure, cholesterol, triglycerides, and glucose remained stable throughout.

The authors are careful to frame the analysis as exploratory rather than confirmatory. It was not powered for formal hypothesis testing, three of the four trials were placebo-controlled for only 12 weeks, and the enrolled population, which excluded women with recent malignancy and abnormal liver parameters, limits generalizability. The incidence-rate calculations also assume a constant hazard over time, which can mask transient risks, and the comparison with population registry data must be interpreted cautiously given the strict eligibility criteria of clinical trials. Longer-term safety monitoring, time-to-event analyses, and real-world post-marketing evidence will be needed to fully characterize the drug’s profile, and a three-year extension study is underway in the breast cancer population from OASIS-4.

Nevertheless, the pooled data provide the most robust safety picture yet for a treatment that many clinicians view as a watershed for menopause care. For women who cannot or choose not to take hormones, and for the growing number of breast cancer survivors whose endocrine therapy triggers severe hot flashes, the findings support elinzanetant as an effective option with a tolerability profile dominated by mild, early, and self-limited central nervous system symptoms. As post-marketing surveillance accumulates in broader and more diverse populations, the drug class that once seemed jeopardized by liver warnings may be finding surer footing.

Subject of Research: Safety and tolerability of elinzanetant, a dual NK-1/NK-3 receptor antagonist for menopausal vasomotor symptoms, in a pooled analysis of four randomized clinical trials

Article Title: Safety and tolerability of elinzanetant: a pooled analysis from four randomized clinical trials

Article References: Safety and tolerability of elinzanetant: a pooled analysis from four randomized clinical trials. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: elinzanetant, menopause, vasomotor symptoms, hot flashes, neurokinin receptor antagonists, liver safety, hepatotoxicity, clinical trials, breast cancer, endometrial safety, pharmacology, women's health

Vasomotor symptoms are not a minor inconvenience. According to the guideline, they are the most common symptoms associated with menopause, affecting up to 80 percent of women. They typically begin during perimenopause, the transitional phase before menstruation stops permanently, when declining and fluctuating levels of reproductive hormones destabilize the body’s temperature regulation. The result is the sudden, often intense sensation of heat known as a hot flash, frequently accompanied by sweating, flushing, and a racing heart, as well as night sweats that can drench sleepwear and interrupt rest. The guideline notes that these episodes can persist well into the postmenopausal years, and that their frequency and severity can disrupt daily activities and erode quality of life.

The physiological story behind vasomotor symptoms is rooted in estrogen. As ovarian function wanes, estrogen levels fall and fluctuate unpredictably, and this hormonal instability is thought to narrow the thermoneutral zone in the brain’s temperature-regulating machinery, making small shifts in core body temperature trigger full heat-dissipation responses. The consequences ripple outward: the guideline highlights that the same hormonal changes can contribute to sleep disturbance, weight fluctuations, anxiety, depression, and genitourinary symptoms, creating a cluster of complaints that often arrive together and compound one another. A woman whose nights are repeatedly broken by hot flashes may also face worsening mood and concentration problems the next day, which is why effective treatment of vasomotor symptoms can have benefits well beyond the episodes themselves.

In developing the recommendation, ACP drew on a related systematic review and meta-analysis, also published in Annals of Internal Medicine, that evaluated pharmacologic treatments for menopausal vasomotor symptoms. The college concluded that estrogen in combination with progestogen, and estrogen monotherapy for women without a uterus, had the most favorable profile of benefits compared with harms among the available options. The addition of progestogen for women with an intact uterus is a long-standing safety principle in hormone therapy, because unopposed estrogen can stimulate the uterine lining and increase the risk of endometrial problems; pairing it with progestogen protects the uterus while preserving estrogen’s effectiveness against hot flashes.

The guideline does not treat hormone therapy as the only option, and it lays out a clear sequence for women who cannot or do not wish to take estrogen. For patients who have contraindications to estrogen therapy or who do not tolerate it, ACP suggests serotonin-norepinephrine reuptake inhibitors, or SNRIs, as second-line treatment, specifically naming desvenlafaxine and venlafaxine. These medications, better known as antidepressants, have demonstrated the ability to reduce the frequency and severity of hot flashes through their effects on neurotransmitter signaling pathways that participate in temperature regulation.

If SNRIs are unsuitable or ineffective, the guideline moves to a third tier of options: a selective serotonin reuptake inhibitor, or SSRI, such as escitalopram or paroxetine; gabapentin, a medication originally developed for seizures and nerve pain that also dampens hot flashes; or a neurokinin receptor antagonist, abbreviated NKra, with elinzanetant and fezolinetant named as the agents in this class. The neurokinin receptor antagonists represent a distinctly newer approach, targeting the neuropeptide signaling pathway in the brain’s thermoregulatory circuitry that becomes overactive as estrogen declines. Their inclusion among third-line options reflects the recent arrival of these drugs as nonhormonal treatments designed specifically for vasomotor symptoms.

Beyond the specific drug rankings, ACP places strong emphasis on how treatment decisions should be made. The college advises clinicians to use an informed decision-making approach, discussing with each patient the benefits and harms of the available options, any contraindications, coexisting medical conditions, and the patient’s own values and preferences. Notably, the guideline also directs physicians to consider the financial burden of treatment and patients’ access to and availability of the various therapies, an acknowledgment that the best medication on paper is of little use if a patient cannot afford it or obtain it. This framing treats the choice of therapy as a collaborative process rather than a one-size-fits-all prescription.

ACP also draws attention to a quieter problem: many women never raise the topic at all. The college encourages physicians to ask their patients directly about their experience with menopausal vasomotor symptoms, because many women may not initiate these discussions on their own. Whether due to embarrassment, the cultural normalization of suffering through menopause, or the belief that nothing effective is available, women’s silence about hot flashes and night sweats can leave treatable symptoms unaddressed for years. By prompting clinicians to open the conversation, the guideline aims to close the gap between the large share of women affected and the smaller share who receive care.

The timing of the guideline reflects a broader shift in how the medical community views menopausal hormone therapy. After years in which safety concerns led many clinicians and patients to avoid estrogen-based treatment, accumulating evidence has allowed organizations to identify the women for whom hormone therapy offers the clearest net benefit, particularly those seeking relief from bothersome vasomotor symptoms. By naming estrogen therapy as first-line, ACP is signaling to internists and primary care physicians, who manage the majority of menopausal care, that withholding hormone therapy from appropriate candidates is no longer the default stance. The guideline’s tiered structure gives clinicians a practical pathway for the many patients who have contraindications to estrogen, such as those with a history of certain hormone-sensitive cancers or cardiovascular events, without leaving them without options.

For the roughly eight in ten women who will experience hot flashes or night sweats as they pass through the menopausal transition, the practical message of the new guideline is that effective treatments exist and that the choice among them can be tailored to individual health circumstances and preferences. Women with a uterus considering first-line therapy will receive estrogen plus progestogen; women without a uterus can receive estrogen alone; those who cannot take estrogen have a defined ladder of nonhormonal alternatives ranging from SNRIs to SSRIs, gabapentin, and neurokinin receptor antagonists. Equally important, the guideline reframes the clinical encounter itself, urging physicians to ask about symptoms that patients may not volunteer and to weigh cost and access alongside efficacy and safety. The full guideline and its accompanying evidence review are published in Annals of Internal Medicine, and together they provide the most current roadmap from the American College of Physicians for managing one of the most common and disruptive experiences in women’s health.

Subject of Research: Clinical guideline recommendations for pharmacologic treatment of menopausal vasomotor symptoms

Article Title: ACP recommends hormonal therapy as a first-line treatment for menopausal vasomotor symptoms

Article References: ACP recommends hormonal therapy as a first-line treatment for menopausal vasomotor symptoms. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: menopause, vasomotor symptoms, hot flashes, hormone therapy, estrogen, progestogen, SNRI, SSRI, gabapentin, neurokinin receptor antagonist, clinical guideline, Annals of Internal Medicine

AMH has long occupied a central place in reproductive endocrinology. Secreted by small growing follicles in the ovary, the hormone serves as a circulating proxy for the size of the resting follicle pool, the reserve that determines both fertility potential and the trajectory toward menopause. In assisted reproduction clinics worldwide, AMH measurements guide ovarian stimulation protocols and counseling about expected response. Yet the hormone’s clinical usefulness in midlife women has remained constrained by two practical problems. First, most existing reference ranges were derived from populations of reproductive-age women, so precise age-specific values for women over 35, and especially those navigating the menopausal transition, have often been lacking. Second, conventional immunoassays can lose analytical sensitivity at the very low concentrations characteristic of late reproductive life, making subtle but clinically meaningful changes difficult to detect and quantify.

To address both limitations, a research team led by Professor Yingying Qin of Shandong University, in collaboration with Professor Ruimin Zheng of the National Center for Women and Children’s Health, drew on a large nationwide cohort of Chinese women aged 35 to 55. By applying an ultrasensitive AMH assay, the investigators were able to measure the hormone with greater precision in precisely the age range where levels approach the floor of detection. This proved particularly important among women aged 44 to 49, a phase the researchers characterize as one of near-depletion, when conventional assays may return values so low that differences between individuals are obscured. The resulting age-specific percentile table, published online on August 17, 2026, in the Chinese Medical Journal, functions as a calibrated chart: a clinician can take a woman’s exact age and her AMH value and locate where she sits relative to the distribution of her peers, seeing at a glance whether her ovarian reserve appears well ahead of or lagging behind the norm for her age.

The percentile framework is more than a descriptive atlas. The team evaluated its clinical utility in a hospital-based care cohort, focusing on women aged 35 to 40 who still planned to conceive. Among these patients, those whose baseline AMH fell below the 10th percentile for their age carried a substantially higher risk of progressing to severely diminished ovarian reserve, defined in the study as an AMH concentration below 0.25 nanograms per milliliter, compared with women whose values sat within the normal percentile range. That distinction matters for fertility counseling. A single AMH reading, interpreted against an age-matched distribution rather than a one-size-fits-all cutoff, can give a woman in her late thirties a quantitative, individualized signal about how quickly her reserve may be declining, informing decisions about the timing of pregnancy attempts or the pursuit of assisted reproduction.

The study’s ambitions extend beyond fertility. Perimenopausal symptoms, particularly vasomotor complaints such as hot flashes and night sweats, are among the most common and most under-recognized problems in routine midlife care, yet they are typically assessed only through subjective questionnaires. The researchers found that among women aged 35 to 55, lower AMH levels were associated with a greater likelihood of more severe perimenopausal symptoms, with the relationship most evident for vasomotor symptoms. This raises the possibility that AMH could serve as an objective biomarker to complement symptom inventories, helping clinicians stratify patients by the likely intensity of their transition and tailor management accordingly, including consideration of hormone replacement therapy when clinically appropriate. The authors are careful to frame this as an association that supports more integrated care rather than a deterministic prediction; symptom experience varies widely among women with similar hormone profiles, and AMH would supplement, not replace, careful clinical assessment.

A third application tested in the study concerns the diagnosis of menopause itself. Clinically, menopausal status is usually inferred from menstrual history together with hormone measurements, but follicle-stimulating hormone and estradiol can fluctuate dramatically during the transition, sometimes producing ambiguous results. Comparing AMH levels between premenopausal and postmenopausal women, the team observed a cliff-like drop, with mean values of 0.187 nanograms per milliliter in premenopausal participants versus 0.043 nanograms per milliliter in those who were postmenopausal. The magnitude of that separation is striking at the group level, but the hormone’s power to classify any individual woman proved moderate, with an overall discriminative performance of around 0.7 on the area under the receiver operating characteristic curve, a standard measure of diagnostic accuracy in which 0.5 indicates chance performance and 1.0 indicates perfect classification.

That moderate AUC carries an important practical message: AMH by itself is not sufficient as a stand-alone diagnostic test for menopause. Menopause remains, fundamentally, a retrospective clinical diagnosis anchored in twelve consecutive months of amenorrhea. However, the study suggests that extremely low AMH values, measured with an ultrasensitive assay, can still provide useful supportive information in clinically challenging situations, for example when a woman’s menstrual pattern is disrupted by contraception or other conditions and her FSH and estradiol results fluctuate across the diagnostic threshold. In such cases, a near-undetectable AMH reading adds a piece of biological evidence that, combined with the rest of the clinical picture, can help clinicians assess where a patient stands in the transition.

The technical achievement underlying these applications lies in the assay itself. At the low concentrations typical of women in their mid-to-late forties, conventional platforms approach their limits of quantification, and small analytical imprecision can translate into large relative errors. An ultrasensitive assay extends the measurable range downward, allowing the near-depletion phase to be characterized rather than lumped into a single undetectable category. That analytical gain is what makes an age-specific percentile table feasible across the full 35-to-55 span: without reliable measurement at the low end, the lower percentiles for older age bands would be statistically unstable and clinically uninterpretable. The nationwide cohort design further strengthens the reference values by capturing the geographic and demographic breadth of the Chinese population, an important consideration given that AMH distributions can vary across ethnic groups and study settings.

Taken together, the new scale addresses practical clinical gaps across both the late reproductive and perimenopausal stages, and the researchers frame its contribution around three integrated goals. Earlier identification means recognizing women at higher risk of low ovarian reserve sooner, providing quantitative support for fertility planning in later reproductive age. Better management means combining AMH profiling with symptom assessment to support more precise handling of perimenopausal complaints and improve quality of life in midlife. Supportive diagnosis means acknowledging that while AMH alone is not an ideal menopause test, very low values measured ultrasensitively can assist clinicians in assessing menopausal status, particularly in complex cases where other reproductive hormones are difficult to interpret. The work was supported by the National Natural Science Foundation of China, the National Key Research and Development Program of China, and several provincial and institutional funders, reflecting the scale of investment in reproductive aging research in China.

For women’s health practice, the study signals a shift toward treating the menopausal transition with the same quantitative rigor long applied to earlier reproductive life. An age-calibrated AMH reference scale gives clinicians a common language for discussing ovarian reserve with patients in their thirties, forties, and fifties, replacing vague reassurances or alarming single cutoffs with a percentile position that evolves with age. It also opens the door to longitudinal use: repeated measurements plotted against the age-specific curve could, in principle, reveal whether an individual woman’s reserve is declining on a typical trajectory or at an accelerated pace, though the current study establishes the cross-sectional framework rather than validating serial monitoring. As ultrasensitive assays become more widely available, the approach developed by Qin, Zheng, and colleagues may prompt parallel reference studies in other populations, a necessary step before the Chinese percentile tables are applied globally. What the study already demonstrates is that the hormonal signature of reproductive aging can be measured, mapped, and translated into clinical decision support across the full arc of midlife, from fertility planning to symptom management to the supportive assessment of menopause itself.

Subject of Research: Age-specific anti-Müllerian hormone reference values for reproductive aging in Chinese women

Article Title: A new scale for reproductive aging in Chinese women based on ultra-sensitive AMH testing

Article References: A new scale for reproductive aging in Chinese women based on ultra-sensitive AMH testing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: AMH, anti-Müllerian hormone, ovarian reserve, reproductive aging, menopause, perimenopause, ultrasensitive assay, fertility, vasomotor symptoms, hormone replacement therapy, Chinese Medical Journal, women's health

The study drew on data from 356 women who had been diagnosed with breast cancer and were interviewed five years later as part of the VICAN5 survey, a large French national cohort designed to follow cancer survivors’ lives across health, work, and psychosocial domains. To characterize sexual dysfunction, the researchers selected five items from the Relationship and Sexuality Scale, a validated instrument covering dimensions of sexual life relevant to cancer survivors. Because sexual dysfunction is multidimensional, encompassing desire, arousal, comfort, and satisfaction, the team applied latent class analysis, a data-driven method that identifies unobserved subgroups within a population based on patterns of responses across multiple indicators. Instead of imposing arbitrary cutoff scores, latent class analysis lets the data reveal how symptoms cluster together in real people.

The analysis pointed decisively to a three-class model. The largest group, comprising 133 women or 37.4 percent of the sample, experienced moderate sexual dysfunction. A second group of 124 women, or 34.8 percent, reported no or low dysfunction. But the third group, 99 women representing 27.8 percent of survivors, reported high sexual dysfunction five years after diagnosis. In other words, nearly two-thirds of women in remission carried at least a moderate burden of sexual problems, and more than one in four carried a heavy one, at a point in their care when routine oncology follow-up has typically shifted focus to surveillance for recurrence rather than quality-of-life issues.

To understand what distinguished women in the higher-severity classes, the researchers used ordinal logistic regression, a statistical approach suited to outcomes that fall into ordered categories, in this case the ordered severity classes of dysfunction. The strongest association by far was psychological: women who reported feeling less sexually attractive had nearly five times the odds of belonging to a higher dysfunction class, with an adjusted odds ratio of 4.72. This finding places body image at the center of the sexual health picture for breast cancer survivors, consistent with a broader literature linking surgical scars, hair loss, weight changes, and altered breast sensation to diminished sexual self-concept and avoidance of intimacy.

Treatment exposures also left measurable marks. Women who had received radiotherapy had 2.36 times the odds of higher dysfunction, and those still taking adjuvant endocrine therapy at the time of the survey had 1.87 times the odds. Endocrine therapies, including tamoxifen and aromatase inhibitors, are taken for years and work by suppressing estrogen signaling, which can induce menopausal symptoms such as vaginal dryness, hot flashes, and decreased libido even in premenopausal women. The finding that current endocrine therapy use remained associated with sexual dysfunction at five years underscores that these drugs’ side effects are not transient inconveniences but persistent burdens that can erode adherence and quality of life.

Persistent physical symptoms emerged as another cluster of risk factors. Women reporting frequent excessive sweating had 1.67 times the odds of higher dysfunction, and those with frequent paresthesia, abnormal tingling or numbness in the breast or arm, had 1.78 times the odds. Both symptoms point to lasting physiological changes from treatment: vasomotor instability driven by endocrine effects, and nerve injury or sensory loss following surgery and radiation. Breast and nipple sensation plays a documented role in sexual response, and its loss is increasingly recognized as a distinct outcome, sometimes described as sensorisexual function, that deserves attention in its own right rather than being dismissed as a minor sensory change.

The analysis also flagged factors that might be modifiable. Women diagnosed after age 50 had 2.30 times the odds of higher dysfunction, a finding that likely reflects the interplay of natural menopause with treatment-induced hormonal changes. Frequent alcohol consumption was associated with 2.00 times the odds, and use of hypnotic medications, typically prescribed for sleep disturbance, with 1.66 times the odds. The hypnotic finding is particularly intriguing because sedative-hypnotic drugs have known effects on sexual function, and sleep disorders themselves are linked to sexual problems in women. Whether hypnotics are a cause, a marker of underlying distress, or both cannot be resolved in a cross-sectional analysis, but the association suggests that sleep management in survivors may have benefits that extend beyond rest.

The VICAN5 cohort itself deserves attention as a model for survivorship research. Funded by the French National Institute of Cancer, the VICAN surveys followed nationally representative samples of cancer patients at two and five years after diagnosis, capturing not only clinical outcomes but employment, social life, and intimate relationships. This breadth allowed the current analysis to situate sexual dysfunction within women’s whole lives rather than within the clinic alone. The study was approved by French ethics and data protection authorities, and all participants gave informed consent, meeting the standards expected of research touching on highly personal subject matter.

Certain limitations temper the conclusions. The analysis is cross-sectional, meaning it captures a single snapshot at five years and cannot establish whether the associated factors preceded the dysfunction or followed from it. The five RSS items, while validated, provide a narrower window on sexual function than comprehensive instruments such as the Female Sexual Function Index, and the sample of 356 women, though drawn from a national survey, may not represent all survivors, particularly those who declined to answer questions about sexuality. Sexual health questions are notoriously subject to underreporting, which means the true prevalence of dysfunction could be even higher than the study suggests.

Even with those caveats, the message for clinical practice is clear and increasingly urgent. The authors argue that sexual health assessment should be built into routine survivorship care for breast cancer, including dedicated oncosexual consultations, psychosexual support for body image concerns, and active management of persistent treatment symptoms such as vasomotor complaints and neuropathic sensations. Recent trials of newer agents for endocrine-therapy-related vasomotor symptoms show that effective options are emerging, and evidence-based non-pharmacological approaches to sleep and distress are available. What has been missing, the study implies, is the will to ask. Most survivors are never asked about their sexual lives by their oncology teams, and most do not raise the topic themselves. A simple, structured screening question at follow-up visits, targeted especially at women reporting feeling less sexually attractive or struggling with persistent symptoms, could open a door that too many women have been left to face alone.

Subject of Research: Patterns and predictors of sexual dysfunction among breast cancer survivors five years after diagnosis

Article Title: Patterns of sexual dysfunction among breast cancer survivors five years after diagnosis: a latent class analysis of the French VICAN5 study

Article References: Radwan, E., Seguin, L., Provansal, M., Mancini, J., & Bouhnik, A.-D. (2026). Patterns of sexual dysfunction among breast cancer survivors five years after diagnosis: a latent class analysis of the French VICAN5 study. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-026-02108-z

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02108-z

Keywords: breast cancer survivors, sexual dysfunction, latent class analysis, VICAN5, adjuvant endocrine therapy, body image, radiotherapy, paresthesia, vasomotor symptoms, survivorship care, hypnotic use, quality of life